NASDAQ: BMGLBasel Medical Group Ltd Stock
$0.92+0.21 (+29.58%)
Updated Dec 12, 2025
BMGL Price
$0.92
Fair Value Price
$1.42
Market Cap
$17.34M
52 Week Low
$0.70
52 Week High
$9.40
P/E
-1.82x
P/B
4.54x
P/S
3.76x
PEG
N/A
Dividend Yield
N/A
Revenue
$8.90M
Earnings
-$9.50M
Gross Margin
77.7%
Operating Margin
-108.67%
Profit Margin
-106.8%
Debt to Equity
2.47
Operating Cash Flow
-$3M
Beta
0.5
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
BMGL Overview
Basel Medical Group Ltd provides healthcare services. The company offers services in the areas of medical specialists, medical supplies and equipment, medical technology, and pharmaceuticals. The company was incorporated in 2023 and is based in Singapore.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine BMGL's potential to beat the market
- BMGL doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Care Facility
Industry Rating
A
BMGL
RankedUnranked of 42
RankedUnranked of 42
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $9.02 | A | |
| $22.50 | A | |
| $9.68 | A |
Be the first to know about important BMGL news, forecast changes, insider trades & much more!
BMGL News
Overview
Due Diligence Score
–
Industry Average (29)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how BMGL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BMGL ($0.92) is undervalued by 35.2% relative to our estimate of its Fair Value price of $1.42 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
BMGL ($0.92) is significantly undervalued by 35.2% relative to our estimate of its Fair Value price of $1.42 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
BMGL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more BMGL due diligence checks available for Premium users.
Valuation
BMGL fair value
Fair Value of BMGL stock based on Discounted Cash Flow (DCF)
Price
$0.92
Fair Value
$1.42
Undervalued by
35.41%
BMGL ($0.92) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
BMGL ($0.92) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
BMGL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
BMGL price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.82x
Industry
15.44x
Market
44.99x
BMGL price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.54x
Industry
5.35x
BMGL is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
BMGL's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
BMGL's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
BMGL's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$13.3M
Liabilities
$9.4M
Debt to equity
2.47
BMGL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
BMGL's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
BMGL vs Medical Care Facility Stocks
Basel Medical Group Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.